Phillip Kantharidis

Senior Research Fellow
Diabetic Complications
Baker Heart and Diabetes Institute
E-mail: phillip.kantharidis@bakeridi.edu.au
Page: http://www.bakeridi.edu.au

Fields of interest: 

Renal fibrosis, microRNA, EMT, TGFβ

 

Recent publications:

Wang B, Komers R, Carew R, Winbanks CE, Xu B, Herman-Edelstein M, Koh P, Thomas M, Jandeleit-Dahm K, Gregorevic P, Cooper ME, Kantharidis P.:
Suppression of microRNA-29 Expression by TGF-β1 Promotes Collagen Expression and Renal Fibrosis.
JASN., 23(2):252-65 (2012)

Liu J, Wang B, Hartono SB, Liu T, Kantharidis P, Middelberg AP, Lu GQ, He L, Qiao SZ.:
Magnetic silica spheres with large nanopores for nucleic acid adsorption and cellular uptake.
Biomaterials, 33(3):970-8 (2012)

Wang B, Koh P, Winbanks C, Coughlan MT, McClelland A, Watson A, Jandeleit-Dahm K, Burns WC, Thomas MC, Cooper ME, Kantharidis P:
miR-200a Prevents renal fibrogenesis through repression of TGF-beta2 expression.
Diabetes, 60:280-287 (2011)

Winbanks CE, Wang B, Beyer C, Koh P, White L, Kantharidis P, Gregorevic P:
TGF-{beta} regulates miR-206 and miR-29 to control myogenic differentiation through regulation of histone deacetylase 4 (HDAC4).
J Biol Chem., 286(16):13805-14 (2011)

Kantharidis P, Wang B, Carew RM, Lan HY.:
Diabetes complications: the microRNA perspective.
Diabetes, 60(7):1832-7 (2011)

Wang B, Herman-Edelstein M, Koh P, Burns W, Jandeleit-Dahm K, Watson A, Saleem M, Goodall GJ, Twigg SM, Cooper ME, Kantharidis P:
E-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-beta.
Diabetes, 59:1794-1802 (2010)